Targeting neddylation E2s: a novel therapeutic strategy in cancer

Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F (UBE2F) are the two NEDD8-conjugating enzymes of the neddylation pathway that take part in posttranslational modification and change the activity of target proteins. The activity of E2 enzymes requires both a 26-residue...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2021-04, Vol.14 (1), p.57-57, Article 57
Main Authors: Zheng, Yi-Chao, Guo, Yan-Jia, Wang, Bo, Wang, Chong, Mamun, M A A, Gao, Ya, Liu, Hong-Min
Format: Article
Language:English
Subjects:
Amino acids
Anticancer treatment
Apoptosis
Autophagy
Binding sites
Cancer
Cancer therapies
Cell cycle
Cell growth
Cullin
Deoxyribonucleic acid
DNA
DNA repair
Enzymes
Health aspects
Hematology
Ligases
Mammals
Neddylation
Oncology
Peptides
Post-translational modification
Proteins
Review
RNA polymerase
Therapeutic targets
Transcription factors
UBE2F
UBE2M
Ubiquitin
Ubiquitin-conjugating enzyme
Ubiquitin-protein ligase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F (UBE2F) are the two NEDD8-conjugating enzymes of the neddylation pathway that take part in posttranslational modification and change the activity of target proteins. The activity of E2 enzymes requires both a 26-residue N-terminal docking peptide and a conserved E2 catalytic core domain, which is the basis for the transfer of neural precursor cell-expressed developmentally downregulated 8 (NEDD8). By recruiting E3 ligases and targeting cullin and non-cullin substrates, UBE2M and UBE2F play diverse biological roles. Currently, there are several inhibitors that target the UBE2M-defective in cullin neddylation protein 1 (DCN1) interaction to treat cancer. As described above, this review provides insights into the mechanism of UBE2M and UBE2F and emphasizes these two E2 enzymes as appealing therapeutic targets for the treatment of cancers.
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-021-01070-w